Some Internet Postings Should Be Exempt From DDMAC Clearance - Sanofi
Executive Summary
FDA should distinguish between drug company postings on static portions of the Internet and those that are part of a conversation when applying requirements on submission of promotional materials prior to their use, Sanofi-Aventis argues